Processa Licenses RX-3117 Patent Family from Ocuphire
shot by IP News Shots / 6:20 pm on 18 June, 2021
Processa Pharmaceuticals, Inc. and Ocuphire Pharma, Inc. have entered into a patent licensing agreement for the latter’s RX-3117 family of patents. As per the terms of the agreement, Processa will have exclusive worldwide rights excluding China, to sub-license, use, manufacture and commercialize RX-3117.
Read more at Seeking Alpha